The influence of rifampicin discontinuation on rifampicin-induced cytochrome P450 enzyme activity

The influence of rifampicin discontinuation on rifampicin-induced cytochrome P450 enzyme activity - The influence of RFP discontinuation on CYP activity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004083

Enrollment

Registered

2010-08-23

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycobacterial infection

Interventions

day-7&gt

day-1: rifampicin 450mg day-7, day0, day3, day7: midazoram 15ug/kg, omeprazole 20mg, dextromethorphan 30mg, losartan 50mg, caffein 100mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All participants must meet the following requirements. :Age more than 20 years :Systolic blood pressure at rest more than 100mmHg :Written informed consent

Exclusion criteria

Exclusion criteria: Exclusion criterias are as follows. :Drug hypersensitivity (particularly to agents included in the studies) :Taking any medication :History of alcohol or drug abuse :History or presence of liver dysfunction :History or presence of tuberculosis :Participation in a clinical trial during the last 6 months prior to the start of the study

Design outcomes

Primary

Measure	Time frame
Assess pharmacokinetics of CYP substrate drugs with or without rifampicin.	—

Countries

Japan

Contacts

Public ContactTaisuke Akamatsu

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026